For eff ective relief
from the symptoms of allergy and hayfever1,2
• Eff ective and fast-acting1,2 • Once daily in adults • Easy–to–take tablets • Available in pack sizes of 7, 14 and 30 tablets
Order now: Pack Size RRP*(£)
(Cetirizine hydrochloride 10mg tablets) Allergy relief for all seasons
Allacan 7s Allacan 14s Allacan 30s
£2.00 £3.00 £4.00
Listed Trade Price (£)
£1.50 £2.25 £3.00
PIP Code
388-5803 388-4376 388-5811
EAN Code
506001394 2990 506001394 4468 506001394 4598
PRESCRIBING INFORMATION Product name: Allacan (Cetirizine hydrochloride 10mg tablets) Indications: Patients 6 years and above: Relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis, relief of chronic idiopathic urticaria. Posology and method of administration: Tablets to be swallowed with water. Patients aged 6 to 12 years: - 5mg twice daily (half tablet twice daily). Patients 12 years and above: - 10mg once daily (one tablet). Patients with moderate to severe renal impairment: - Dosage adjustment to be individualised in line with renal function – See Summary of Product Characteristics (SmPC), Patients with hepatic and renal impairment: Dosage adjustment is recommended – See SmPC. Contraindications: Known hypersensitivity to cetirizine or any of the excipients; severe renal impairment, galactose intolerance, lapp- lactase defi ciency and glucose-galactose malabsorption. Special warnings: Use with caution in breastfeeding and epileptic patients. Undesirable eff ects: somnolence, fatigue, dizziness, headache dry mouth, eye accommodation, isolated elevation of hepatic enzymes. Product Licence Holder: Bristol Laboratories Limited, Unit 3, Canalside, Northbridge Road, Berkhamsted, Hertfordshire, HP4 1EG (PL 17907/ 0046) Date of Authorisation: 07/09/2004 Recommended Price: 7 Tablets £2.00, 14 Tablets £3.00, 30 Tablets £4.00. Date of Prescribing Information: 27/02/2015 GSL
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows monitoring of the benefi t/risk balance of the medicinal product. Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Bristol Laboratories Medical Information Department on Telephone: 0044 (0) 1442 200 922
References: 1. Allacan SmPC - Jan 2015 2. Zhang L et al. The Clinical Use of Cetirizine in the Treatment of Allergic Rhinitis, Pharmacology 2013; 92:14-25.
*Recommended Retail Price Date of preparation: March 2015 Code: UK/ALL/ADV10ga/03/2015
Quality • Consistency • Excellence
www.bristol-labs.co.uk
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60